Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

NCT07480382 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Initially Unresectable Hepatocellular Carcinoma

Interventions

PROCEDURE: Liver Venous Deprivation (LVD)
PROCEDURE: Conventional Transarterial Chemoembolization(C-TACE)
DRUG: Tislelizumab combined with Lenvatinib

Sponsor

Hong Wu